Abbott Will “Actively Promote” Synthroid Despite Generic Entrants
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will not cease marketing efforts in the face of AB-rated levothyroxine generics from Mylan and Sandoz. U.S. Synthroid sales jumped 24% during the quarter due to increased share and favorable year-over-year comparisons.
You may also be interested in...
Abbott/Boehringer's Mobic Sales Surge On COX-2 Safety Concerns
Sales of the non-steroidal anti-inflammatory agent jumped 177% in the fourth quarter on the heels of Merck's withdrawal of Vioxx. Abbott expects sales of Mobic to reach $1 bil. in 2005. The levothyroxine brand Synthroid is retaining 70% of the share it held before entry of generic competition.
Abbott/Boehringer's Mobic Sales Surge On COX-2 Safety Concerns
Sales of the non-steroidal anti-inflammatory agent jumped 177% in the fourth quarter on the heels of Merck's withdrawal of Vioxx. Abbott expects sales of Mobic to reach $1 bil. in 2005. The levothyroxine brand Synthroid is retaining 70% of the share it held before entry of generic competition.
Synthroid Holding 75% Of Its Pre-Generic Script Share, Abbott Says
Script share for the levothyroxine brand is "within our range of expectations" since AB-rated generics entered the market, CFO Freyman says. Abbott predicted generic erosion for Synthroid would be less than that for other drugs due, in part, to the product's narrow therapeutic range.